Promising RNAi Treatment Lowers Blood Pressure in Groundbreaking Study
Alnylam Pharmaceuticals' RNA interference treatment, zilebesiran, demonstrated the ability to reduce blood pressure for six months in a mid-stage clinical trial. The company aims to develop zilebesiran as an add-on or alternative to daily blood pressure medications.